- Home
- EXAS
as 01-17-2025 4:00pm EST
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 10.5B | IPO Year: | N/A |
| Target Price: | $72.80 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $40.62 - $79.62 | Next Earning Date: | 02-19-2025 |
| Revenue: | $2,692,328,000 | Revenue Growth: | 11.91% |
| Revenue Growth (this year): | 11.81% | Revenue Growth (next year): | 11.52% |
Stock Insider Trading Activity of Exact Sciences Corporation (EXAS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Conroy Kevin T | EXAS | President and CEO | Nov 13 '24 | Buy | $51.35 | 19,500 | $1,001,325.00 | 1,074,191 |
Latest Exact Sciences Corporation News
EXAS Breaking Stock News: Dive into EXAS Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Why Exact Sciences (EXAS) Is Crashing?
Morningstar Research
2 days ago
Analyst Report: Exact Sciences Corporation
Investor's Business Daily
2 days ago
Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'
Motley Fool
2 days ago
2 Healthcare Stocks to Buy Hand Over Fist in January
Simply Wall St.
4 days ago
High Growth Tech Stocks To Watch In January 2025
MT Newswires
5 days ago
Exact Sciences Expects 10% Growth in Q4 Revenue
Business Wire
6 days ago
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
Zacks
10 days ago
Should Exact Sciences Stock Stay in Your Portfolio Right Now?
Compare EXAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXAS Exact Sciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.